𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reply: Botulinum type A therapy during pregnancy

✍ Scribed by David P. Charles; William J. Newman; Thomas L. Davis; Bimal B. Padaliya; Chandler E. Gill; Anna I. Abramovitch

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
35 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

We thank Drs. Bodkin, Maurer, and Wszolek 1 for their interest in our article on botulinum type A therapy during pregnancy, 2 which appeared in the November 2004 issue of Movement Disorders. The overall use of BOTOX for both treatment and cosmetic purposes continues to rise. Incidental exposures of pregnant women to the drug are likely to become more common. Because there are no other equally effective treatments for some conditions, the issue of its use in pregnant women is a very important one. Similar to the woman with cervical dystonia who was alluded to in the response letter, other patients have indubitably experienced severe discomfort in the absence of BOTOX treatments during a pregnancy. More investigation is needed and we encourage physicians to continue to report their experiences with the use of neurotoxins during pregnancy.

πŸ“œ SIMILAR VOLUMES

Botulinum toxin type A therapy during pr
Botulinum toxin type A therapy during pregnancy
✍ William J. Newman; Thomas L. Davis; Bismal B. Padaliya; Cassondra D. Covington; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 41 KB

## Abstract Injection with botulinum toxin type A (Botox) is a safe and efficacious treatment for idiopathic cervical dystonia. We present the first case report of clinical Botox treatment during pregnancy. This patient underwent four apparently uncomplicated full‐term pregnancies while receiving r

Botulinum toxin type A therapy during pr
Botulinum toxin type A therapy during pregnancy
✍ Cynthia L. Bodkin; Kenneth B. Maurer; Zbigniew K. Wszolek πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 43 KB
Botulinum toxin antibody type A titres a
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy
✍ Dirk Dressler; Hans Bigalke πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 145 KB

## Abstract In some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop. Thirteen patients (eight

Therapy and prevention of thrombotic thr
Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies
✍ Ezra, Yossef; Rose, Michal; Eldor, Amiram πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 511 KB

Thrombotic thrombocytopenic purpura (TrP) is a severe multisystem disorder of unknown pathogenesis, with preference to women. The mortality rate of patients with TTP was 90% until the introduction of plasma therapy that Increased the survival rate to 70-80%, with minimal or no sequelae. Of the survi